NASDAQ:ANAB AnaptysBio Q3 2026 Earnings Report $46.09 -1.80 (-3.77%) As of 01:28 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast AnaptysBio EPS ResultsActual EPSN/AConsensus EPS -$1.84Beat/MissN/AOne Year Ago EPSN/AAnaptysBio Revenue ResultsActual RevenueN/AExpected Revenue$25.56 millionBeat/MissN/AYoY Revenue GrowthN/AAnaptysBio Announcement DetailsQuarterQ3 2026Date11/3/2026TimeAfter Market ClosesConference Call DateWednesday, November 4, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile AnaptysBio Earnings HeadlinesAnaptysBio (NASDAQ:ANAB) Cut to Hold at Wall Street ZenOctober 4 at 1:07 AM | americanbankingnews.comAnaptysBio (NASDAQ:ANAB) Director Hollings Renton Sells 5,000 Shares of Company StockOctober 3, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 7 at 1:00 AM | Chaikin Analytics (Ad)JPMorgan Chase & Co. Has Lowered Expectations for AnaptysBio (NASDAQ:ANAB) Stock PriceOctober 2, 2026 | americanbankingnews.comAnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash PerformanceSeptember 26, 2026 | finance.yahoo.comAnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?September 26, 2026 | insidermonkey.comSee More AnaptysBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AnaptysBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AnaptysBio and other key companies, straight to your email. Email Address About AnaptysBioAnaptysBio (NASDAQ:ANAB) is a clinical-stage biotechnology company focused on developing antibody-based medicines for inflammatory and autoimmune diseases. The company uses its antibody discovery and engineering capabilities to identify therapies designed to modulate immune-system targets involved in disease. AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to target CD200R1, a receptor involved in regulating immune-cell activity. The company has evaluated rosnilimab in inflammatory and autoimmune conditions, including rheumatoid arthritis and ulcerative colitis. Its development programs and priorities may change as clinical studies progress. Founded in 2005 and headquartered in San Diego, California, AnaptysBio has also pursued collaborations and licensing arrangements with larger pharmaceutical companies. Historically, antibodies discovered using the company’s technology have contributed to programs such as dostarlimab, an immune checkpoint inhibitor subsequently developed and commercialized by another company. AnaptysBio is led by President and Chief Executive Officer Hamid Tabatabai.View AnaptysBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Wall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the StakesInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
